Guggenheim Capital LLC Abb Vie Inc. Transaction History

Guggenheim Capital LLC

$14 Billion
Q1 2024

A detailed history of Guggenheim Capital LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Guggenheim Capital LLC holds 314,685 shares of ABBV stock, worth $52.2 Million. This represents 0.41% of its overall portfolio holdings.

Number of Shares

314,685

Previous 298,502 5.42%

Holding current value

$52.2 Million

Previous $46.3 Million 23.88%

% of portfolio

0.41%

Previous 0.35%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$159.82 - $182.1 $2.59 Million - $2.95 Million	16,183 Added 5.42%	314,685 $57.3 Million
Q4 2023 Feb 14, 2024	SELL	$137.6 - $154.97 $7.4 Million - $8.34 Million	-53,797 Reduced 15.27%	298,502 $46.3 Million
Q3 2023 Nov 14, 2023	SELL	$133.59 - $154.65 $9.64 Million - $11.2 Million	-72,151 Reduced 17.0%	352,299 $52.5 Million
Q2 2023 Aug 11, 2023	SELL	$132.51 - $164.9 $5.26 Million - $6.55 Million	-39,714 Reduced 8.56%	424,450 $57.2 Million
Q1 2023 May 10, 2023	SELL	$144.61 - $166.54 $15 Million - $17.2 Million	-103,456 Reduced 18.23%	464,164 $74 Million

Q4 2022 Feb 14, 2023	SELL	$138.31 - $165.87 $10.9 Million - $13 Million	-78,473 Reduced 12.15%	567,620 $91.8 Million
Q3 2022 Nov 14, 2022	SELL	$134.21 - $153.93 $6.13 Million - $7.03 Million	-45,663 Reduced 6.6%	646,093 $86.7 Million
Q2 2022 Aug 15, 2022	SELL	$137.62 - $174.96 $16.5 Million - $21 Million	-120,223 Reduced 14.81%	691,756 $106 Million
Q1 2022 May 16, 2022	BUY	$131.98 - $163.75 $2.08 Million - $2.58 Million	15,730 Added 1.98%	811,979 $132 Million
Q4 2021 Feb 14, 2022	BUY	$107.43 - $135.93 $5.48 Million - $6.93 Million	51,017 Added 6.85%	796,249 $108 Million
Q3 2021 Nov 15, 2021	BUY	$106.4 - $120.78 $1.43 Million - $1.63 Million	13,472 Added 1.84%	745,232 $80.4 Million
Q2 2021 Aug 13, 2021	BUY	$105.21 - $117.21 $682,286 - $760,106	6,485 Added 0.89%	731,760 $82.4 Million
Q1 2021 May 13, 2021	SELL	$102.3 - $112.62 $911,390 - $1 Million	-8,909 Reduced 1.21%	725,275 $78.5 Million
Q4 2020 Feb 16, 2021	SELL	$80.49 - $108.67 $85,158 - $114,972	-1,058 Reduced 0.14%	734,184 $78.7 Million
Q3 2020 Nov 13, 2020	SELL	$85.91 - $100.83 $5.25 Million - $6.16 Million	-61,122 Reduced 7.68%	735,242 $64.4 Million
Q2 2020 Aug 14, 2020	BUY	$73.37 - $98.18 $7.47 Million - $9.99 Million	101,789 Added 14.65%	796,364 $78.2 Million
Q1 2020 Jun 02, 2020	SELL	$64.5 - $97.79 $2.6 Million - $3.93 Million	-40,234 Reduced 5.48%	694,575 $52.9 Million
Q4 2019 Feb 14, 2020	BUY	$72.13 - $90.25 $6.58 Million - $8.24 Million	91,269 Added 14.18%	734,809 $65.1 Million
Q3 2019 Nov 14, 2019	SELL	$62.98 - $75.72 $817,417 - $982,769	-12,979 Reduced 1.98%	643,540 $48.7 Million
Q2 2019 Aug 14, 2019	SELL	$65.7 - $83.98 $1.58 Million - $2.02 Million	-24,087 Reduced 3.54%	656,519 $47.7 Million
Q1 2019 May 15, 2019	BUY	$77.14 - $90.79 $6.69 Million - $7.87 Million	86,734 Added 14.6%	680,606 $54.9 Million
Q4 2018 Feb 14, 2019	SELL	$77.85 - $96.01 $9.66 Million - $11.9 Million	-124,066 Reduced 17.28%	593,872 $54.7 Million
Q3 2018 Nov 14, 2018	SELL	$88.91 - $98.84 $5.35 Million - $5.95 Million	-60,188 Reduced 7.73%	717,938 $67.9 Million
Q2 2018 Aug 14, 2018	SELL	$89.78 - $106.23 $63.9 Million - $75.6 Million	-711,508 Reduced 47.76%	778,126 $72.1 Million
Q1 2018 May 15, 2018	SELL	$92.01 - $123.21 $22.8 Million - $30.5 Million	-247,522 Reduced 14.25%	1,489,634 $141 Million
Q4 2017 Feb 14, 2018	BUY	$89.56 - $98.21 $8.54 Million - $9.36 Million	95,342 Added 5.81%	1,737,156 $168 Million
Q3 2017 Nov 14, 2017	BUY	$69.85 - $89.22 $115 Million - $146 Million	1,641,814	1,641,814 $146 Million

Others Institutions Holding ABBV

# of Institutions

3,652

Shares Held

1.24B

Call Options Held

15.5M

Put Options Held

11.6M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $293B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Guggenheim Capital LLC with notifications on news.

Account

Guggenheim Capital LLC Abb Vie Inc. Transaction History